Sara Patel is an associate in the London office of Latham & Watkins and advises healthcare, life sciences, artificial intelligence, technology companies and their investors on a range of corporate and technology transactional matters and related regulatory support.

She advises clients at all stages including emerging companies and global market leaders on transactional and regulatory matters within London and internationally including the GCC on:

  • Strategic licensing and collaborations
  • Manufacturing, supply, and distribution agreements
  • Research and development agreements
  • Joint ventures
  • Mergers and acquisitions
  • IPOs and follow-on offerings
  • Diverse financing transactions including royalty purchase and sales
  • Life sciences and AI regulatory
  • Regulatory compliance

Prior to joining Latham, Ms. Patel has also spent time as in-house counsel at Gilead Sciences in its EMEA HQ, including in Gilead’s Silicon Valley and UAE offices. She has a degree in Biological Sciences and draws on her life sciences industry background and commercial perspective to her legal representations.

Ms. Patel also maintains an active pro bono practice in relation to intellectual property, commercial and regulatory matters and Ms. Patel regularly speaks and writes on healthcare, life sciences, artificial intelligence, and digital health related topics.

Ms. Patel’s experience includes advising:

Strategic Intellectual Property Transactions

  • Pharmaceutical Investment Company (Lifera), a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) of Saudi Arabia on a strategic collaboration and JV with Centogene, a German life sciences company focused on data-driven answers in rare and neurodegenerative diseases, to provide AI driven diagnostics expertise and the establishment of advanced laboratory and bioinformatics infrastructure in KSA 
  • CollPlant Biotechnologies, a regenerative medicine company, in a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company
  • A leading US medical devices company on a strategic IP license agreement for the development and commercialization of its medical technology platform
  • GSK on variety of matters including supply arrangements
  • A world-leading GCC hospital in relation to agreements for the global supply of medicinal product and medical devices
  • A UK-based DNA/RNA sequencing company on a variety of intellectual property and complex commercial agreements*
  • A KSA based pharmaceutical company in relation to its strategic license and distribution agreements*

Joint Ventures and M&A

  • atai Life Sciences in a strategic investment in Beckley Psytech to accelerate the clinical development of short-duration psychedelics, on intellectual property and commercial matters 
  • A leading investor in a series C financing round for a digital health company that develops and provides AI driven non-invasive medical diagnostics solutions to support healthcare provider diagnosis, pharmaceutical development, patient monitoring, and treatment decision-making
  • Norgine, a Netherlands-based specialty pharmaceutical company on regulatory matters in its US$2 billion sale to Goldman Sachs
  • A multinational world-leading pharmaceutical company on intellectual property, commercial and regulatory matters in its US$1.5 billion acquisition of a UK biotech company
  • Astorg on its binding agreement to acquire CordenPharma, a leading pharmaceutical contract development and manufacturing organization, from ICIG, a privately owned industrial group
  • Silver Lake Partners on its €3.5 billion investment in IVC Evidensia, a leading European veterinary care provider
  • Novo Holdings on leading a Series D funding round for Quanta Dialysis Technologies, a medical technology leader delivering on its vision for more flexible and accessible dialysis care and acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
  • Nordic Capital in its US$846 million acquisition of Advanz Pharma, a UK-based specialty pharmaceutical company
  • A global medical device company on its joint venture with a world-leading multinational company for the manufacture and distribution of spectacle lenses
  • Owens & Minor, Inc. a global healthcare solutions company on the sale of its European logistics business, Movianto, to EHDH Holding Group*
  • CBPE Capital on its acquisition of Simbec-Orion, an international CRO*
  • A leading Middle Eastern pharmaceutical company on its JV with an Indian generics company*


  • Various pharmaceutical and medical technology companies regarding pharmacovigilance, clinical trials and other study agreements
  • A global social media platform in connection with its medical device product launch in the UAE
  • A leading Germany-based medical device company in connection with the supply and distribution of medical devices in the UAE
  • Various global pharmaceutical clients in relation to their regulatory compliance programs and interactions with HCPs*
  • Amplifon SpA in connection with its medical device product launch in the UK and EU* 
  • A UK headquartered pharmaceutical company in relation to product launch and the supply of medicinal product to the UAE, Kuwait, and Qatar*

*Matter handled prior to joining Latham

Bar Qualification

  • England and Wales (Solicitor)


  • Graduate Diploma in Law and Legal Practice Course, BPP Law School, London
  • BSc Biological Sciences, Warwick University

Languages Spoken

  • English
  • Urdu